<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197492</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-525</org_study_id>
    <secondary_id>HSCK-002</secondary_id>
    <nct_id>NCT04197492</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas</brief_title>
  <official_title>A Phase II Study of Hypofractionated Stereotactic Radiotherapy Combined With Anlotinib in Patients With Recurrent High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in
      Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after
      radiotherapy. Secondary endpoints included progress-free survival, objective response rate,
      cognitive function, quality of life, toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Original histopathologically proven diagnosis World Health Organization (WHO) Grade 3/4
      glioma patients who underwent surgery, chemoradiotherapy and adjuvant chemotherapy (Stupp
      Protocol). Recurrence based on Response Assessment in Neuro-Oncology (RANO) criteria and/or
      histopathology. Intervention included CyberKnife hypofractionated stereotactic radiotherapy
      (25Gy/5fx) with Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the start of treatment to the date of death or the last follow-up, up to approximately 24 months</time_frame>
    <description>Estimated using the Kaplan-Meier method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the start of treatment to the date of disease progression or death, up to approximately 24 months</time_frame>
    <description>Estimated using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or progressive disease (PD), up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Assessment in Neuro-Oncology (RANO) prior to progression or any further therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score (QoL): European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) version 3.0</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>EORTC QLQ-C30 (version 3.0) questionnaire to evaluate the quality of life. All scales range in score from 0 to 100. A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>Mini-Mental State Exam (MMSE, score range 0 to 30) to evaluate the cognitive function. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) 5.0 to assess the toxicity. Estimated using an exact binomial distribution together with 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>HSRT With Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.
Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Stereotactic Radiotherapy</intervention_name>
    <description>Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)</description>
    <arm_group_label>HSRT With Anlotinib</arm_group_label>
    <other_name>Hypofractionated Stereotactic Radiosurgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.</description>
    <arm_group_label>HSRT With Anlotinib</arm_group_label>
    <other_name>AL3818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-70 years of age;

          2. Karnofsky performance status (KPS) ≥ 60;

          3. Original histopathologically proven diagnosis World Health Organization (WHO) Grade
             3/4 glioma;

          4. Underwent surgery, chemoradiotherapy and adjuvant chemotherapy (Stupp Protocol) after
             initial diagnosis, recurrent based on the Response Assessment in Neuro-Oncology (RANO)
             criteria and/or histopathologically proven;

          5. Measurable disease;

          6. Estimated survival of at least 3 months;

          7. Hgb &gt; 9 gm; absolute neutrophil count (ANC) &gt; 1500/μl; platelets &gt; 100,000; Creatinine
             &lt; 1.5 times the upper limit of laboratory normal value; Bilirubin &lt; 2 times the upper
             limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or
             serum glutamate oxaloacetate transaminase (SGOT) &lt; 3 times the upper limit of
             laboratory normal value;

          8. Signed informed consent form;

          9. Agreed to participate the follow-up.

        Exclusion Criteria:

          1. Prior invasive malignancy unless disease free;

          2. Received re-irradiation;

          3. More than 3 relapses or evidence of subtentorial recurrent disease or tumor greater
             than 6 cm in maximum diameter;

          4. Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGFR;

          5. Pregnancy or or nursing mothers;

          6. Participated in other trials after diagnosis of recurrent;

          7. Influence factors toward oral medications;

          8. Patients with CTCAE5.0 grade 3+ bleeding;

          9. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial
             infarction above grade II, poorly controlled arrhythmias (including men with QTc
             interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV
             Insufficient function, or cardiac color Doppler ultrasound examination indicates left
             ventricular ejection fraction (LVEF) &lt;50%;

         10. Long-term unhealed wounds or fractures;

         11. History of organ transplantation;

         12. Serious diseases that endanger patients' safety or affect patients' completion of
             research,according to the researchers' judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enmin Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun Guan, MD</last_name>
    <phone>+86 15301987553</phone>
    <email>yguan10@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Wang, MD</last_name>
    <phone>+86 13120557273</phone>
    <email>wangxinck@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CyberKnife Center, Department of Neurosurgery, Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enmin Wang, MD</last_name>
      <email>wangem@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wuthrick EJ, Curran WJ Jr, Camphausen K, Lin A, Glass J, Evans J, Andrews DW, Axelrod R, Shi W, Werner-Wasik M, Haacke EM, Hillman GG, Dicker AP. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):369-75. doi: 10.1016/j.ijrobp.2014.05.034. Epub 2014 Aug 4.</citation>
    <PMID>25104067</PMID>
  </reference>
  <reference>
    <citation>Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.</citation>
    <PMID>28870792</PMID>
  </reference>
  <reference>
    <citation>Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V, Enrici RM. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol. 2013 Jan;111(2):187-94. doi: 10.1007/s11060-012-0999-9. Epub 2012 Nov 6.</citation>
    <PMID>23129347</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 15, 2019</last_update_submitted>
  <last_update_submitted_qc>December 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Enmin Wang</investigator_full_name>
    <investigator_title>Head of CyberKnife Center, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypofractionated Stereotactic Radiotherapy</keyword>
  <keyword>Recurrent High-grade Glioma</keyword>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

